These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 12019070)

  • 1. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.
    Peláez T; Alcalá L; Alonso R; Rodríguez-Créixems M; García-Lechuz JM; Bouza E
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1647-50. PubMed ID: 12019070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Assessment of susceptibility to metronidazole and vancomycin of Clostridium difficile strains isolated between 1998-2002].
    Pituch H; Obuch-Woszczatyński P; Glinka D; Łazińska B; Meisel-Mikołajczyk F; Łuczak M
    Med Dosw Mikrobiol; 2003; 55(3):253-8. PubMed ID: 14702667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro activity of linezolid against Clostridium difficile.
    Peláez T; Alonso R; Pérez C; Alcalá L; Cuevas O; Bouza E
    Antimicrob Agents Chemother; 2002 May; 46(5):1617-8. PubMed ID: 11959617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of anti-Clostridium difficile activity of thuricin CD, vancomycin, metronidazole, ramoplanin, and actagardine, both singly and in paired combinations.
    Mathur H; O'Connor PM; Hill C; Cotter PD; Ross RP
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2882-6. PubMed ID: 23571539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997.
    Barbut F; Decré D; Burghoffer B; Lesage D; Delisle F; Lalande V; Delmée M; Avesani V; Sano N; Coudert C; Petit JC
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2607-11. PubMed ID: 10543736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest.
    Wong SS; Woo PC; Luk WK; Yuen KY
    Diagn Microbiol Infect Dis; 1999 May; 34(1):1-6. PubMed ID: 10342100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluoroquinolone resistance and Clostridium difficile, Germany.
    Zaiss NH; Witte W; Nübel U
    Emerg Infect Dis; 2010 Apr; 16(4):675-7. PubMed ID: 20350385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clostridium difficile bacteremia, Taiwan.
    Lee NY; Huang YT; Hsueh PR; Ko WC
    Emerg Infect Dis; 2010 Aug; 16(8):1204-10. PubMed ID: 20678312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.
    Citron DM; Tyrrell KL; Merriam CV; Goldstein EJ
    Antimicrob Agents Chemother; 2012 Mar; 56(3):1613-5. PubMed ID: 22183166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo activities of the novel Ketolide RBx 14255 against Clostridium difficile.
    Kumar M; Mathur T; Barman TK; Ramkumar G; Bhati A; Shukla G; Kalia V; Pandya M; Raj VS; Upadhyay DJ; Vaishnavi C; Chakrabarti A; Das B; Bhatnagar PK
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5986-9. PubMed ID: 22869573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diversity of Circulating
    Martínez-Meléndez A; Tijerina-Rodríguez L; Collins N; Baines SD; Morfin-Otero R; Camacho-Ortíz A; Villarreal-Treviño L; Garza-González E
    Microb Drug Resist; 2021 Dec; 27(12):1672-1676. PubMed ID: 34037477
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital.
    Aspevall O; Lundberg A; Burman LG; Akerlund T; Svenungsson B
    Antimicrob Agents Chemother; 2006 May; 50(5):1890-2. PubMed ID: 16641471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A multicenter-based study on epidemiology, antibiotic susceptibility and risk factors of toxigenic Clostridium difficile in hospitalized patients in southwestern Iran.
    Sedigh Ebrahim-Saraie H; Heidari H; Amanati A; Bazargani A; Alireza Taghavi S; Nikokar I; Kalantar K; Motamedifar M
    Infez Med; 2018 Dec; 26(4):308-315. PubMed ID: 30555133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial activity of LFF571 and three treatment agents against Clostridium difficile isolates collected for a pan-European survey in 2008: clinical and therapeutic implications.
    Debast SB; Bauer MP; Sanders IM; Wilcox MH; Kuijper EJ;
    J Antimicrob Chemother; 2013 Jun; 68(6):1305-11. PubMed ID: 23420839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.
    Locher HH; Seiler P; Chen X; Schroeder S; Pfaff P; Enderlin M; Klenk A; Fournier E; Hubschwerlen C; Ritz D; Kelly CP; Keck W
    Antimicrob Agents Chemother; 2014; 58(2):892-900. PubMed ID: 24277020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raja 42, a novel gamma lactam compound, is effective against Clostridioides difficile.
    Fong A; Ross M; Boudreau J; Nokhbeh R; Tilbe K; Lee H
    PLoS One; 2021; 16(9):e0257143. PubMed ID: 34492076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tcdA-negative and tcdB-positive Clostridium difficile ST81 clone exhibits a high level of resistance to fluoroquinolones: a multi-centre study in Beijing, China.
    Cheng JW; Liu C; Kudinha T; Xiao M; Fan X; Yang CX; Wei M; Liang GW; Shao DH; Xiong ZJ; Hou X; Yu SY; Wang Y; Yang QW; Su JR; Xu YC
    Int J Antimicrob Agents; 2020 Jul; 56(1):105981. PubMed ID: 32330584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Epidemiological study of Clostridium difficile strains isolated in Jean-Verdier-René-Muret hospitals from 2001 to 2007].
    Poilane I; Fantinato C; Cruaud P; Collignon A
    Pathol Biol (Paris); 2008; 56(7-8):412-6. PubMed ID: 18842360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the in vitro antibacterial activity of Ramizol, fidaxomicin, vancomycin, and metronidazole against 100 clinical isolates of Clostridium difficile by broth microdilution.
    Wolfe C; Pagano P; Pillar CM; Shinabarger DL; Boulos RA
    Diagn Microbiol Infect Dis; 2018 Nov; 92(3):250-252. PubMed ID: 30042035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic determinants of resistance to antimicrobial therapeutics are rare in publicly available Clostridioides difficile genome sequences.
    Kolte B; Nübel U
    J Antimicrob Chemother; 2024 Jun; 79(6):1320-1328. PubMed ID: 38598696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.